149 related articles for article (PubMed ID: 33133686)
1. Development of a novel thymidylate synthase (TS) inhibitor capable of up-regulating P53 expression and inhibiting angiogenesis in NSCLC.
Li XY; Wang DP; Lu GQ; Liu KL; Zhang TJ; Li S; Mohamed O K; Xue WH; Qian XH; Meng FH
J Adv Res; 2020 Nov; 26():95-110. PubMed ID: 33133686
[TBL] [Abstract][Full Text] [Related]
2. Discovery of novel thymidylate synthase (TS) inhibitors that influence cancer angiogenesis and metabolic reprogramming in NSCLC cells.
Dong G; Li YH; Guo JS; Lin QQ; Deng MY; Xue WH; Li XY; Meng FH
Eur J Med Chem; 2023 Oct; 258():115600. PubMed ID: 37437348
[TBL] [Abstract][Full Text] [Related]
3. Discovery of N-phenyl-(2,4-dihydroxypyrimidine-5-sulfonamido) phenylurea-based thymidylate synthase (TS) inhibitor as a novel multi-effects antitumor drugs with minimal toxicity.
Li XY; Zhang TJ; Kamara MO; Lu GQ; Xu HL; Wang DP; Meng FH
Cell Death Dis; 2019 Jul; 10(7):532. PubMed ID: 31296849
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of N-phenyl-(2,4-dihydroxypyrimidine-5-sulfonamido)benzoyl hydrazide derivatives as thymidylate synthase (TS) inhibitors and as potential antitumor drugs.
Li XY; Liang JW; Mohamed O K; Zhang TJ; Lu GQ; Meng FH
Eur J Med Chem; 2018 Jun; 154():267-279. PubMed ID: 29807332
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of novel uracil derivatives bearing 1, 2, 3-triazole moiety as thymidylate synthase (TS) inhibitors and as potential antitumor drugs.
Lu GQ; Li XY; Mohamed O K; Wang D; Meng FH
Eur J Med Chem; 2019 Jun; 171():282-296. PubMed ID: 30927565
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer.
Del Bufalo D; Desideri M; De Luca T; Di Martile M; Gabellini C; Monica V; Busso S; Eramo A; De Maria R; Milella M; Trisciuoglio D
Mol Cancer; 2014 Oct; 13():230. PubMed ID: 25301686
[TBL] [Abstract][Full Text] [Related]
7. High pemetrexed sensitivity of docetaxel-resistant A549 cells is mediated by TP53 status and downregulated thymidylate synthase.
Kuo WT; Tu DG; Chiu LY; Sheu GT; Wu MF
Oncol Rep; 2017 Nov; 38(5):2787-2795. PubMed ID: 28901493
[TBL] [Abstract][Full Text] [Related]
8. Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer.
Ceppi P; Rapa I; Lo Iacono M; Righi L; Giorcelli J; Pautasso M; Billè A; Ardissone F; Papotti M; Scagliotti GV
Int J Cancer; 2012 Apr; 130(8):1777-86. PubMed ID: 21618517
[TBL] [Abstract][Full Text] [Related]
9. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
Takezawa K; Okamoto I; Tanizaki J; Kuwata K; Yamaguchi H; Fukuoka M; Nishio K; Nakagawa K
Mol Cancer Ther; 2010 Jun; 9(6):1647-56. PubMed ID: 20530710
[TBL] [Abstract][Full Text] [Related]
10. Astaxanthin enhances pemetrexed-induced cytotoxicity by downregulation of thymidylate synthase expression in human lung cancer cells.
Liao KS; Wei CL; Chen JC; Zheng HY; Chen WC; Wu CH; Wang TJ; Peng YS; Chang PY; Lin YW
Regul Toxicol Pharmacol; 2016 Nov; 81():353-361. PubMed ID: 27693704
[TBL] [Abstract][Full Text] [Related]
11. Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer.
Takezawa K; Okamoto I; Okamoto W; Takeda M; Sakai K; Tsukioka S; Kuwata K; Yamaguchi H; Nishio K; Nakagawa K
Br J Cancer; 2011 May; 104(10):1594-601. PubMed ID: 21487406
[TBL] [Abstract][Full Text] [Related]
12. Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer.
Kawabata S; Chiang CT; Tsurutani J; Shiga H; Arwood ML; Komiya T; Gills JJ; Memmott RM; Dennis PA
Oncotarget; 2014 Feb; 5(4):1062-70. PubMed ID: 24658085
[TBL] [Abstract][Full Text] [Related]
13. The deubiquitinating enzyme UCHL1 promotes resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase.
Ding X; Gu Y; Jin M; Guo X; Xue S; Tan C; Huang J; Yang W; Xue M; Zhou Q; Wang W; Zhang Y
Theranostics; 2020; 10(13):6048-6060. PubMed ID: 32483437
[No Abstract] [Full Text] [Related]
14. Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer.
Markova B; Hähnel PS; Kasper S; Herbertz S; Schuler M; Breitenbuecher F
J Cancer Res Clin Oncol; 2012 Apr; 138(4):545-54. PubMed ID: 22203472
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of dUTPase induces synthetic lethality with thymidylate synthase-targeted therapies in non-small cell lung cancer.
Wilson PM; LaBonte MJ; Lenz HJ; Mack PC; Ladner RD
Mol Cancer Ther; 2012 Mar; 11(3):616-28. PubMed ID: 22172489
[TBL] [Abstract][Full Text] [Related]
16. Dexamethasone pretreatment impairs the thymidylate synthase inhibition mediated flare in thymidine salvage pathway activity in non-small cell lung cancer.
Chen X; Yang Y; Katz SI
PLoS One; 2018; 13(8):e0202384. PubMed ID: 30142195
[TBL] [Abstract][Full Text] [Related]
17. Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells.
Tekle C; Giovannetti E; Sigmond J; Graff JR; Smid K; Peters GJ
Br J Cancer; 2008 Sep; 99(5):750-9. PubMed ID: 18728666
[TBL] [Abstract][Full Text] [Related]
18. Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells.
Wu MF; Hsiao YM; Huang CF; Huang YH; Yang WJ; Chan HW; Chang JT; Ko JL
J Thorac Oncol; 2010 Aug; 5(8):1143-51. PubMed ID: 20559153
[TBL] [Abstract][Full Text] [Related]
19. Green tea-derived theabrownin suppresses human non-small cell lung carcinoma in xenograft model through activation of not only p53 signaling but also MAPK/JNK signaling pathway.
Xiao X; Guo L; Dai W; Yan B; Zhang J; Yuan Q; Zhou L; Shan L; Efferth T
J Ethnopharmacol; 2022 Jun; 291():115167. PubMed ID: 35271947
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells.
Giovannetti E; Lemos C; Tekle C; Smid K; Nannizzi S; Rodriguez JA; Ricciardi S; Danesi R; Giaccone G; Peters GJ
Mol Pharmacol; 2008 Apr; 73(4):1290-300. PubMed ID: 18187583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]